Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
Fukumoto W, Okamura S, Tamai M, Arima J, Kawahara I, Fukuda I, Mitsuke A, Sakaguchi T, Sugita S, Matsushita R, Tatarano S, Yamada Y, Nakagawa M, Enokida H, Yoshino H. Fukumoto W, et al. Among authors: arima j. BMC Cancer. 2024 Oct 29;24(1):1333. doi: 10.1186/s12885-024-13109-5. BMC Cancer. 2024. PMID: 39472827 Free PMC article.
Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1α in sunitinib-resistant renal cell carcinoma.
Fukumoto W, Yoshino H, Horike SI, Kawakami I, Tamai M, Arima J, Kawahara I, Mitsuke A, Sakaguchi T, Inoguchi S, Meguro-Horike M, Tatarano S, Enokida H. Fukumoto W, et al. Among authors: arima j. Cancer Sci. 2023 Oct;114(10):3946-3956. doi: 10.1111/cas.15914. Epub 2023 Aug 6. Cancer Sci. 2023. PMID: 37545017 Free PMC article.
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, Fukuda I, Mitsuke A, Sakaguchi T, Inoguchi S, Matsushita R, Nakagawa M, Tatarano S, Yamada Y, Enokida H. Kawahara I, et al. Among authors: arima j. Mol Oncol. 2024 Sep;18(9):2196-2211. doi: 10.1002/1878-0261.13684. Epub 2024 Jun 14. Mol Oncol. 2024. PMID: 38874588 Free PMC article.
Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma.
Yoshino H, Tatarano S, Tamai M, Tsuruda M, Iizasa S, Arima J, Kawakami I, Fukumoto W, Kawahara I, Li G, Sakaguchi T, Inoguchi S, Yamada Y, Enokida H. Yoshino H, et al. Among authors: arima j. Biochem Biophys Res Commun. 2022 Nov 19;630:71-76. doi: 10.1016/j.bbrc.2022.09.056. Epub 2022 Sep 16. Biochem Biophys Res Commun. 2022. PMID: 36150242 Free article.
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Sakaguchi T, Mitsuke A, Osako Y, Yamada Y, Takeyama H, Ogawa R, Takahashi K, Hirohata Y, Yamamoto S, Arima J, Fukumoto W, Sugita S, Inoguchi S, Matsushita R, Yoshino H, Tatarano S, Enokida H. Sakaguchi T, et al. Among authors: arima j. BMC Nephrol. 2024 Apr 8;25(1):124. doi: 10.1186/s12882-024-03561-7. BMC Nephrol. 2024. PMID: 38589827 Free PMC article.
Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients.
Mitsuke A, Ohbo T, Arima J, Osako Y, Sakaguchi T, Matsushita R, Yoshino H, Tatarano S, Yamada Y, Sasaki H, Tanabe T, Fukuzawa N, Tanaka H, Nishio Y, Hideki E, Harada H. Mitsuke A, et al. Among authors: arima j. PLoS One. 2023 Oct 11;18(10):e0287059. doi: 10.1371/journal.pone.0287059. eCollection 2023. PLoS One. 2023. PMID: 37819994 Free PMC article.
146 results